PMV Pharmaceuticals (NASDAQ:PMVP) and Vivos Therapeutics (NASDAQ:VVOS) Critical Comparison

PMV Pharmaceuticals (NASDAQ:PMVP) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Volatility and Risk

PMV Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the S&P 500.

Profitability

This table compares PMV Pharmaceuticals and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Vivos Therapeutics	-121.37%	-849.22%	-96.11%

Analyst Recommendations

This is a summary of recent recommendations for PMV Pharmaceuticals and Vivos Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1	0	1	1	2.67
Vivos Therapeutics	1	1	2	0	2.25

PMV Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 281.68%. Vivos Therapeutics has a consensus price target of $2.75, indicating a potential upside of 370.01%. Given Vivos Therapeutics’ higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than PMV Pharmaceuticals.

Valuation & Earnings

This table compares PMV Pharmaceuticals and Vivos Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.49)	-0.88
Vivos Therapeutics	$17.44 million	0.46	-$21.17 million	($2.07)	-0.28

Vivos Therapeutics has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

PMV Pharmaceuticals beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.